Public Policy News

Biocom Applauds Congressman Juan Vargas on Introducing Biomedical Funding Legislation

On July 31st, 2014, Congressman Juan Vargas (CA-51) introduced H.Res. 709, a resolution to help support the development of new treatments and cures by bringing attention to the “Valley of Death” in life sciences funding, a funding gap between basic research and clinical development. The resolution recognizes the importance of transformative breakthroughs in biomedicine, the existence of the valley of death, and the need to consider innovative financial structures to help fund translational research.

The resolution has been referred to the House Committee on Energy and Commerce. Joining Rep. Vargas as cosponsors include fellow Californian Representatives Mike Honda (D-17), Jeff Denham (R-10), and Doris Matsui (D-6), among others. Click here to view the resolution.

Biocom has consistently advocated for increased access to capital and looks forward to continuing working with Congressman Juan Vargas to help support and fund the early stages of the drug development process.

« Return to Table of Contents

Dan Hart and Michael Mueller Invite You to Join Them on Biocom’s IP Committee

As co-chairs of Biocom’s Intellectual Property and Patent Law Committee, we invite you to join us!

Our IP committee brings the Southern California legal and life science communities together through discussion of important intellectual property and patent law issues affecting our members, and serves as a forum to improve working relations between the USPTO and industry.  The committee meets at noon on the fourth Friday of each month and members may participate in the meeting in person at Biocom’s offices or telephonically.

Committee members are given the unique opportunity to advise Biocom Public Policy Committee on IP matters and recommend Biocom positions on regulatory and legislative proposals. They monitor, review, and comment on new IP and patent law bills, current IP issues, PTO guidances, reports and requests for comments, White House executive actions, and Federal Circuit and Supreme Court decisions. In addition, committee members enjoy networking, exchanging best practices, and discussing matters of common interest around food and refreshments.

Committee members remain at the forefront of new IP developments through regular updates on important IP issues, legislation, guidances, and Congressional hearings overseeing IP matters or featuring PTO personnel, as well as reports on public forums held at PTO headquarters by Biocom staff in DC.

In the past year, the Committee discussed important matters, including patent litigation reform (“patent trolls”), PTO subject matter eligibility guidance (“Myriad-Mayo”), PTO fee diversion, RCE backlog, sequestration, relevant Supreme Court cases, and the IP Chapter of the Trans-Pacific Partnership (TPP), among others.

If you’d like to be part of this exciting group or have any questions, please contact Laure Fabrega of Biocom’s staff. The Committee is open to all Biocom members (industry and providers).

We hope to hear from you,

Dan Hart
Knobbe, Martens, Olson & Bear
Biocom IP Committee Co-Chair

Michael Mueller
Conatus Pharmaceuticals
Biocom IP Committee Co-Chair

« Return to Table of Contents

Save the Date--Biocom's Annual Facilities Reception to be Held October 28th

Save the Date: Tuesday, October 28th Biocom willbe hosting its annual Facilities Reception in partnership with theInternational Society for Pharmaceutical Engineering (ISPE). This event isgeared towards facility managers and service providers but is open to allBiocom members. Mark your calendars for a relaxed evening to mingle with otherfacility managers and enjoy interaction with other organizations. Last year,this event drew over 150 attendees!

« Return to Table of Contents